Compare Novo Nordisk A/S (NVO) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Novo Nordisk A/S trades at $38.4 (market cap $165.31B), while Vanguard S&P 500 Growth Index Fund ETF trades at $87.27 (market cap $27.10B). The key difference: Novo Nordisk A/S is far larger — about 6.1× Vanguard S&P 500 Growth Index Fund ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Vanguard S&P 500 Growth Index Fund ETF pays none. Which is the better fit depends on your goals.
| NVO | VOOG | |
|---|---|---|
Market Cap | $165.31B | $27.10B |
Volume | 11,432,838 | 1,178,312 |
Sector | Health | Broad Market / Factor |
52-Week High | $63.98 | $87.81 |
52-Week Low | $35.29 | $65.32 |
Typical Hold Time | 116 Days | — |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
VOOG trades at $87.69, down slightly by 0.14% on the day, with technical indicators showing mixed signals—bullish moving averages but bearish oscillators including an overbought RSI. The ETF, tracking the S&P 500 Growth Index, has delivered strong long-term returns, with recent news highlighting institutional buying and outperformance versus peers. Key support sits at $87, resistance at $88.
Outlook remains positive for long-term growth investors given VOOG's low expense ratio and historical outperformance, though near-term risks include tech sector concentration and market volatility. The ETF's focus on large-cap growth stocks positions it well for sustained appreciation, but investors should be cautious of valuation extremes in growth segments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
